- Home
- ACRS vs EVG Comparison
ACRS vs EVG Comparison
Compare ACRS & EVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- EVG
- Stock Information
- Founded
- ACRS 2012
- EVG 2005
- Country
- ACRS United States
- EVG United States
- Employees
- ACRS N/A
- EVG N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- EVG Investment Managers
- Sector
- ACRS Health Care
- EVG Finance
- Exchange
- ACRS Nasdaq
- EVG Nasdaq
- Market Cap
- ACRS 132.0M
- EVG 149.9M
- IPO Year
- ACRS 2015
- EVG N/A
- Fundamental
- Price
- ACRS $2.24
- EVG $11.19
- Analyst Decision
- ACRS Strong Buy
- EVG
- Analyst Count
- ACRS 5
- EVG 0
- Target Price
- ACRS $11.00
- EVG N/A
- AVG Volume (30 Days)
- ACRS 656.6K
- EVG 49.4K
- Earning Date
- ACRS 03-04-2025
- EVG 01-01-0001
- Dividend Yield
- ACRS N/A
- EVG 8.68%
- EPS Growth
- ACRS N/A
- EVG N/A
- EPS
- ACRS N/A
- EVG N/A
- Revenue
- ACRS $27,079,000.00
- EVG N/A
- Revenue This Year
- ACRS N/A
- EVG N/A
- Revenue Next Year
- ACRS N/A
- EVG N/A
- P/E Ratio
- ACRS N/A
- EVG N/A
- Revenue Growth
- ACRS 26.35
- EVG N/A
- 52 Week Low
- ACRS $0.95
- EVG $9.13
- 52 Week High
- ACRS $5.17
- EVG $10.86
- Technical
- Relative Strength Index (RSI)
- ACRS 39.59
- EVG 54.97
- Support Level
- ACRS $2.11
- EVG $11.14
- Resistance Level
- ACRS $2.42
- EVG $11.27
- Average True Range (ATR)
- ACRS 0.15
- EVG 0.10
- MACD
- ACRS 0.00
- EVG -0.01
- Stochastic Oscillator
- ACRS 26.53
- EVG 55.56
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
About EVG Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest
Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.